Stifel Nicolaus analyst Clémence Thiers has maintained their bullish stance on 0QAV stock, giving a Buy rating on March 31.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clémence Thiers has given his Buy rating due to a combination of factors that highlight Nanobiotix’s promising future prospects. The company has demonstrated solid financial stability, with a cash position that ensures operational visibility well into mid-2026, bolstered by strategic amendments to their partnership with J&J. This partnership has not only shifted significant financial responsibilities to J&J but also strengthened Nanobiotix’s clinical momentum, particularly with the pivotal NANORAY-312 trial and the newly launched CONVERGE study.
Moreover, Nanobiotix’s clinical advancements across various programs, including pancreatic and lung cancers, have shown promising results. The interim analysis of the NANORAY-312 trial, expected in 2026, could be a significant catalyst for the company. Additionally, the company’s innovative approach, such as the “pipeline-in-a-product” thesis, and promising preclinical data from Curadigm, add layers of potential growth beyond oncology, making the stock an attractive buy for investors.
According to TipRanks, Thiers is an analyst with an average return of -19.6% and a 17.39% success rate.
In another report released on March 31, H.C. Wainwright also maintained a Buy rating on the stock with a €10.00 price target.